Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by Noteable


T.ONC

RE:Dance with the one who brotcha

Speaks soundly of returning institutional confidence.

September 4, 2024

T.ONC

RE:RE:RE:RE:RE:RE:Why the rise in stock price and volume?

Research Capital Corporation and Ventum Financial Corporation, both...

September 4, 2024

T.ONC

RE:RE:RE:Why the rise in stock price and volume?

That will be a long-time coming ... if ever !

September 4, 2024

T.ONC

RE:Dance with the one who brotcha

Tell me more about nothing Buckeroo .... 

September 4, 2024

T.ONC

RE:Why the rise in stock price and volume?

Should read: Institutional buying happening.

September 4, 2024

T.ONC

RE:Why the rise in stock price and volume?

Buying happening.

September 4, 2024

T.ONC

Dance with the one who brotcha

Research Capital Corporation reappears on the ONC.TO buy side after first...

September 4, 2024

T.ONC

RE:CAR-T update

September 03, 2024 - Arsenal Biosciences, the CAR-T cell therapy company has...

September 4, 2024

T.ONC

RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

August 29, 2024 - (Bloomberg) -- House Republican leaders plan votes early...

September 3, 2024

T.ONC

RE:RE:RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill

Should read: " ... Pfizer's right to its trastuzumab-deruxtecan...

September 3, 2024

T.ONC

RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

June 2024 -  AstraZeneca and Daiichi Sankyo are now developing...

September 2, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill

As lawyers at Sullivan IP Solutions see it, Pfizer shouldn’t have gone to the...

September 2, 2024

T.ONC

RE:RE:RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill

The board's decision in Seagen is not surprising. Rather, it is...

September 2, 2024

T.ONC

RE:RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill

For Pfizer and it's US$43 Billion acquisition of Seagen and the...

September 2, 2024

T.ONC

RE:RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill

February 23, 2024, -  The latest chapter in the complex and multifaceted...

September 2, 2024

T.ONC

Sanofi Phase 3 drug stumbles but still filing for approval

September 02, 2024 - Sanofi is still set on taking its multiple sclerosis (MS...

September 2, 2024

T.ONC

RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill

August 28, 2024 - The USPTO’s May 2024 proposed anti-patent thicket rule...

September 2, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024

In 2021 the US imposed changes to the way it allows companies to deduct R&...

September 2, 2024

T.ONC

RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024

In April 2024 Deloitte reported on how the current R&D operating model...

September 1, 2024

T.ONC

RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024

Big Pharma has been listening and has restructured their in-house R&D...

September 1, 2024

Featured Company